Pharma RSS Digest - 2026-08-05

Overview

The pharma tape this cycle is shaped by a pair of high-stakes regulatory events that cut in opposite directions. Jazz Pharmaceuticals delivered a strong earnings beat alongside a Priority Review and August 25 PDUFA date for its HER2-positive gastroesophageal adenocarcinoma program, reinforcing bullish sentiment in oncology. In sharp contrast, Capricor Therapeutics absorbed a punishing 9–3 advisory committee vote against its Duchenne muscular dystrophy cell therapy, with shares shedding roughly 80% in a week and at least nine analyst downgrades. Broader sector signal is light, with surviving items skewed toward discovery-stage announcements, operational restructuring at larger players, and a routine contrast-media recall. The next fortnight is dominated by two PDUFA dates (Capricor on August 22 and Jazz's Ziihera on August 25) that will set the tone heading into mid-August.

Key Developments

Jazz Pharmaceuticals posted record Q2 2026 revenues of $1.2 billion (+16% year-over-year) and raised full-year guidance to $4.60–$4.75 billion, with double-digit growth across its epilepsy and oncology franchises. Xywav reached $471M (+13%), Epidiolex hit $292M (+16%), and Zepzelca grew 42% to $106M. Newer launches are ramping: Ziihera in biliary tract cancer posted $15M in its debut quarter, and Modeyso generated $48M with more than 600 patients treated since launch. Importantly, the FDA granted Priority Review for zanidatamab combinations in first-line HER2-positive gastroesophageal adenocarcinoma, locking in a PDUFA date of August 25, 2026, and Jazz says it is ready to launch immediately upon approval. The company also secured Breakthrough Therapy designation in pretreated HER2-positive colorectal cancer and reported NEJM publication of HERIZON-GEA-01. What to watch: the August 25 PDUFA decision for Ziihera in 1L GEA, the Q3 second interim OS analysis from HERIZON-GEA-01, and whether Zepzelca's planned Q3 labeling supplement to remove the 2L SCLC indication gains FDA traction.

Regulatory / CRL

Capricor Therapeutics saw its stock collapse roughly 80% over a single week after an FDA advisory committee voted 9–3 against recommending approval of its cell therapy Deramiocel for Duchenne muscular dystrophy cardiomyopathy. The negative outcome followed an FDA staff briefing from July 27 that concluded HOPE-3 data do not provide substantial evidence of effectiveness, citing post-hoc statistical changes and a hypersensitivity imbalance (42% Deramiocel vs. 15% placebo) that raised functional-unblinding concerns. Capricor pushed back publicly, with CEO Linda Marbán arguing the agency relied on an obsolete draft statistical analysis plan. Shares fell from $19.70 to a $2.97 low before partially recovering to close the week at $3.85, with at least nine analyst firms downgrading and price targets cut 82–97%. The PDUFA date is set for August 22. What to watch: whether the FDA follows the panel's negative signal at the August 22 decision, how the dispute over the statistical analysis plan version is resolved, and whether Capricor pursues appeals, additional trials, or partnership options for the program.

Jazz Pharmaceuticals fda approval update

Watchlist

• Liebel-Flarsheim recalled one lot of OPTIRAY 350 Imaging Bulk Package 500mL vials (lot 25ZF3670) due to particulate contamination including plastic, stainless steel, and glass; the recall is to the user level across the U.S. and Mexico, with no adverse events reported. [link]
• Workforce contractions continue across the industry, with Bristol Myers Squibb adding 206 more layoffs at its Lawrenceville, NJ site, Astellas closing Universal Cells' Seattle office (50 jobs), Replimune cutting 63 in Woburn after a second FDA rejection of RP1, and BioNTech shutting its Singapore mRNA plant by February 2027 (85 employees). [link]
• A first-in-human case series combined phage therapy with fecal microbiota transplantation in three women with recurrent E. coli UTIs, reporting reduced antibiotic use and improved quality of life over two years; a controlled clinical trial under the EU-funded REPhRAME project is slated to begin in June 2027. [link]
• Cumberland Pharmaceuticals completed its $100M Apotex transaction and pivoted to a development-stage model, paying a $1.50 per share special dividend while retaining four Phase 2 ifetroban programs; early Vanderbilt data showed a statistically significant mortality reduction (p=0.037) but a non-significant recurrence reduction (p=0.09) in cancer metastasis. [link]
• Innogen Pharmaceuticals' Suzhou facility received PIC/S GMP certification from Brazil's ANVISA, clearing a path for international registration of its GLP-1 receptor agonist Efsubaglutide Alfa, which is also moving into an adolescent obesity Phase Ib in China and a once-monthly dosing Phase II in Australia. [link]